contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lifecare-receives-ethics-approval-to-initiate-first-in-human-trial-in-norway

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lifecare is a Norwegian company operating in medical technology. The company specializes in research and development of solutions for diabetes. The microsensors are injected under the skin of the patient's wrist, and also function as a real-time update of the patient's glucose level. In addition, the technology provides an alarm sensor and access to historical data on the patient's glucose level. The company was established in 2006 and is headquartered in Bergen, Norway.

Lifecare

Bergen, Norway, 5 August 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management, is pleased to announce...

<div class="mfn-preamble"><p><strong>Bergen, Norway, 5 August 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management, is pleased to announce that it has received approval from the Regional Committee for Medical and Health Research Ethics (REK) in Norway for its planned first-in-human trial of the implantable GCM sensor.</strong></p></div><div class="mfn-body"><p>This marks a significant milestone, bringing Lifecare one step closer to initiating regulatory testing of its wireless glucose sensor for human use. The approved trial is designed to assess the safety, tolerability, and glucose-sensing accuracy of the implant in individuals with type 1 diabetes.</p><p>“We are grateful for REK’s endorsement of our study protocol. This approval reflects the scientific and ethical integrity of our work. It is a key step toward bringing a discreet, reliable and user-friendly CGM solution to people living with diabetes,” says Joacim Holter, CEO of Lifecare ASA.</p><p>The REK approval is conditional upon minor documentation updates and does not represent the final regulatory clearance to initiate the trial. Lifecare is currently awaiting final approval from the Norwegian Medicines Agency (Direktoratet for medisinske produkter), the national authority responsible for clinical trial authorization, before the trial can begin.</p><p>The first-in-human trial will be conducted in Norway and Germany, in collaboration with leading academic and clinical partners. Professor Simon Dankel, a recognized expert in metabolic research and head of the Research Unit for Health Surveys (RUHS) at the University of Bergen, will serve as Principal Investigator. The RUHS in Bergen will host the Norwegian clinical trial site.</p><p>This milestone follows previously announced technical verifications confirming achievements demonstrating that Lifecare’s GCM system meets core radio frequency (RF) and electromagnetic compatibility (EMC) requirements. These successful tests demonstrated the device’s ability to wirelessly transmit glucose date safely and reliably, a prerequisite for real-world use.</p><p>Together, the technical verifications and ethics approval highlight Lifecare’s consistent progress toward regulatory readiness and clinical evaluation of its implantable CGM technology.</p></div><div class="mfn-footer mfn-6f66f307be9c"><p><strong class="mfn-heading-1">About us</strong><br>Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("<strong>CGM</strong>") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.</p></div><div class="mfn-footer mfn-contacts mfn-742f7fc5e6f2"><p><strong class="mfn-heading-1">Contacts</strong><br>For further information, please contact:<br><br>Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40</p><p>Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42<br><br></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/5d1c1e5f-2185-4ff4-968d-3bf3f473cdfe/lifecare-receives-ethics-approval-to-initiate-first-in-human-trial-in-norway.pdf" class="mfn-generated mfn-primary">Lifecare receives ethics approval to initiate first-in-human trial in Norway</a></p></div>